VERTEX PHARMACEUTICALS INC / MA (VRTX)
Pharmaceutical Preparations
Latest Price
$519.51
TTM P/E
30.26
Normalized P/E
47.63
Div Yield
--
Book Value
79.75
P/B Ratio
6.51
Valuation metrics
adjust assumptions →EPS: $15.32
Book value / share: $73.49
Formula: √(22.5 × EPS × BVPS)
Graham Number
$159.16
69% downside
Norm. op. income: $2.9B (median of 7yr)
Tax rate: 15%
Discount rate: 10%
Growth assumption: zero (EPV is a no-growth value)
Earnings Power Value
$121.33
77% downside
Base FCF: $3.3B (median of recent 5yr)
Growth: 5%/yr (median YOY, capped at 25%)
Discount rate: 10%
Terminal growth: 3%
Projection horizon: 10 years
DCF Fair Value
$245.35
53% downside
EPS: $15.32
Target P/E: 48×
Formula: EPS × P/E
P/E Fair Value
$735.36
+42% upside
Institutional Ownership
95.2% held by institutions| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| Capital World Investors | 26.12M | $12.97B | 10.31% | +746.9K | 2026-06-30 |
| BlackRock, Inc. | 24.11M | $11.97B | 9.52% | +139.9K | 2026-06-30 |
| Capital Research Global Investors | 19.49M | $9.68B | 7.69% | -1.64M | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 16.58M | $8.24B | 6.54% | +67.9K | 2026-06-30 |
| STATE STREET CORP | 11.87M | $5.90B | 4.69% | +141.3K | 2026-06-30 |
| Invesco Ltd. | 8.04M | $4.00B | 3.17% | +5.48M | 2026-06-30 |
| JPMORGAN CHASE & CO | 6.52M | $3.26B | 2.57% | +478.1K | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 6.02M | $2.98B | 2.38% | -121.8K | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.88M | $2.42B | 1.93% | -266.6K | 2026-06-30 |
| Capital International Investors | 4.70M | $2.33B | 1.85% | -430.9K | 2026-06-30 |